Orthopedic innovation strategist and medtech entrepreneur to guide SutureTech’s next phase of growth

‍

Durham, NC — December 2, 2025 — SutureTech, a surgeon-founded medical device company pioneering advanced soft tissue repair solutions, announced the appointment of Ken Gall to its Board of Directors. This addition strengthens the company’s commercialization and strategic growth plans as well as technical leadership as SutureTech prepares to scale following the limited-market launch of its flagship product, the RapidFix™ All-Suture Dual Anchor Mattress Repair System. The system, used for the fixation of soft tissue to bone during orthopedic surgical procedures, features a dual-anchor, all-suture design that provides compression and stabilization at the repair site.

‍

A Strategic Fit at a Key Inflection Point

As SutureTech transitions from regulatory success to commercial execution, Gall’s deep expertise in successful MedTech company commercial execution, bold and visionary innovation, and his deep industry network will be instrumental. His insights will help guide development, commercialization, and long-term pipeline planning, reinforcing SutureTech’s commitment to solutions that meet the demands of today’s operating rooms.

‍

Advancing Technical Leadership

Professor Gall is a leading authority in biomaterials, biomechanics, and 3D-printed medical implants. He received his BS, MS, and PhD from the University of Illinois at Urbana-Champaign in Mechanical Engineering and is a Professor in the Department of Mechanical Engineering & Materials Science at Duke University. Over his career, he has earned a number of distinguished honors, including the ASEE Curtis McGraw Award, the Presidential Early Career Award for Scientists & Engineers (PECASE), and the ASME Gold Medal, recognizing his contributions to engineering research and education.

‍

In addition to his academic achievements, Gall has a strong entrepreneurial track record. He is the Co-Founder and Chief Commercial Officer (CCO) of restor3d, a company focused on patient-specific 3D-printed orthopedic implants. His prior ventures and experience with acquisitions, such as MedShape and Vertera, further illustrate his ability to bridge scientific innovation and commercial medical device development.

‍

“I’m excited to join the SutureTech board and partner with a surgeon-founded company that is deeply committed to solving real surgical challenges,” said Ken Gall. “The RapidFix all-suture dual-anchor system represents a compelling combination of clinical insight, engineering craftsmanship, and surgical usability. I look forward to contributing my experience in biomaterials, orthopedic innovation, and scaling early-stage medical technologies to help SutureTech advance its next generation of musculoskeletal repair solutions.”

‍

Leadership Perspective

“Ken Gall brings world-class engineering and innovation insights, deep orthopedic start-up commercialization experience evidenced by his multiple successful exits and the tremendous ambition and growth of Restore3d where he serves as CCO. His deep network with the field is also a great asset,” said Dr. Oke Anakwenze, CEO and Founder of SutureTech. “His appointment bolsters our board precisely at the moment when SutureTech is moving from regulatory clearance to market entry. With RapidFix™ now cleared and our upcoming limited-market launch, Ken will help guide our product roadmap execution, manufacturing strategy, and long-term pipeline development. We believe this step strengthens our foundation for growth and reinforces our commitment to pioneering the future of tendon and ligament repair.”

‍

Commercialization & Growth Strategy

Following its 510(k) clearance, SutureTech is set to initiate a limited-market rollout in Q4 2025, building clinical adoption and operational readiness. The company is simultaneously planning a broader U.S. commercial launch, leveraging partnerships with key opinion leaders (KOLs), strategic distribution channels, and ongoing product pipeline development.

‍

Ken Gall’s appointment comes at a pivotal moment; his commercial and technical leadership will not only support SutureTech through its initial market entry but also fuel future strategic innovations. Gall’s experience guiding early-stage orthopedic technologies to market maturity adds a valuable layer of technical and strategic assurance as SutureTech expands its portfolio.

‍

About SutureTech

SutureTech is a surgeon-founded medical device company focused on advancing soft tissue and tendon repair. Based in Durham, North Carolina, SutureTech develops internal fixation implants and surgical instruments designed to support efficient, reliable procedures across a range of orthopedic applications.

Built on clinical insight and driven by innovation, SutureTech brings together engineering precision and real-world surgical experience to create solutions that meet the demands of today’s operating rooms. Each product reflects our commitment to quality, anatomical adaptability, and procedural consistency.

‍

To learn more, visit www.suturetech.com
__________________________
Media Contact
SutureTech
Contact@SutureTech.com

‍

‍